纳米药物在胰腺癌治疗上的进展  

Nanomedicines for pancreatic cancer treatment:recent progress

作　　者：王智弘 花苏榕[1] 廖泉[1] WANG Zhihong;HUA Surong;LIAO Quan(Department of General Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院基本外科,北京100730

出　　处：《中国普通外科杂志》2022年第3期386-396,共11页China Journal of General Surgery

摘　　要：胰腺癌恶性度高,预后差,常规治疗药物及靶向药物对其治疗效果不佳。其中,胰腺癌的肿瘤微环境对其耐药性的形成有重要作用。纳米药物因合适的粒径、在外周循环中的高稳定性以及高渗透长滞留效应,再结合如光敏、pH敏感等策略控制药物的释放,从而有效地通过肿瘤微环境靶向癌细胞,是治疗胰腺癌的新思路。笔者回顾了目前胰腺癌治疗中纳米药物的治疗策略,包括铁死亡诱导型纳米药物、结合传统化疗药物或小干扰核糖核酸、光动力药物纳米载体以及一些其他的策略,并汇总了近期的进展、相关的临床试验及目前面临的问题。Pancreatic cancer is a highly malignant tumor with dismal prognosis and poor responses to classical chemotherapeutic agents and targeted drugs.Thereinto,tumor microenvironment of pancreatic cancer plays an important role in the development of drug resistance.Nanomedicines are promising candidates for the treatment of pancreatic cancer,because of the advantages of appropriate size and high stability in circulation as well as the enhanced permeability and retention effect,in combination with the strategies such as photosensitive and p H-response controlled drug release,they can effectively penetrate through the tumor microenvironment and target at the cancer cells.Here,the authors review the strategies for using nanomedicines in the treatment of pancreatic cancer,including ferroptosis-inducing nanomedicines,conventional chemotherapeutic agent-or si RNA-loaded nanocarriers,photodynamic nanoagents and some other strategies,and also summarize the recent progress,relevant clinical trials and current problems.

关 键 词：胰腺肿瘤 纳米医学 肿瘤微环境 铁死亡 综述 

分 类 号：R735.9[医药卫生—肿瘤]